headerseite_chip
headerseite_nerv3
headerseite_nerv2
headerseite_befruchtung
headerseite_nerv1
headerseite_bakterien
headerseite_dna
headerseite_binaer
headerseite_neurotrans
headerseite_erythrozyten
headerseite_wabe
headerseite_nerv1b
headerseite_nerv4

cappella_logo 

Combating cancer through novel approaches to protein-protein interaction inhibitor libraries

 

 

Date / Duration

2007-2009, 36 months

Funding

6th Framework Programme for Research and Technological Development of the European Commission (FP6); STREP

Budget

4'914'700 €

Partners

9 companies and universities form 7 countries

  

cappellabild

 

Description

The CAPPELLA project was funded under the 6th Framework Programme for Reseach and Technological Development (FP6). The consortium with nine partners has been coordinated by the SME Evolva SA. The aim of the project was to develop a series of innovative small-ligand tools and libraries that allow new approaches to the inhibition of protein-protein interactions (PPI) in cancer.

The inhibition of PPI is one of the most promising approaches to the development of novel cancer therapies. Because many PPI occur within the cell they can only be targeted by small molecules. But because PPI differ structurally from more classic drug targets, such as enzymes and receptors, existing compounds have generally delivered disappointing results.

During the project, the consortium has developed functional assays for three chosen cancer targets. CAPPELLA was a unique opportunity to integrate novel in-silico, chemical, genetic and ADME-based approaches in the design, synthesis and optimization of libraries and compounds. At the end of the project, researchers were able to identify six new compound families acting on the three targets.

Read here the final report of the projet and learn more about the research results.

Tasks EUrelations AG

EUrelations contributed substantially to the preparation of the successful proposal. EUrelations supported the coordinator during the project.